Table 9.
Series of meningiomas and respective percentages of ER expression.
| Authors, year, country | ER % ± SD | Observations |
|---|---|---|
| Current paper | 2.1 | 96 grade I |
| Korhonen et al., 2006, Finland (11) | 41.6 | 407 grade I primary tumors. Weak immunoreactivity. |
| Kandemir et al., 2010, Turkey (71) | 0 | 53 grade I |
| Kärjä et al., 2010, Finland/Sweden (13) | Primary: 40.0 ± 2.5 Recurrent: 33.3 ± 3.3 |
59 grade I (p = 0.105) |
| Abdelzaher et al., 2011, Egypt (51) | 3.33 | 60 grade I |
| Blankenstein et al., 2000, Holland (89) | 13.0 | 396 grades I, II and III. Predominance of ER/PR+ |
| Konstantinidou et al., 2003, Grécia (82) | 35.4 | 49 grades I and II |
| Barbosa-Coutinho, Hilbig, 2006, Brazil (54) | 0 | Grades I, II, and III |
| Custer et al., 2006, USA (88) | 1.0 | 140 grades I, II, and III |
| Omulecka et al., 2006, Poland (62) | 48.0 | 46 grade I and 18 grade II (n = 64) No relation with grade, sex, Ki67 or PR |
| Taghipour et al., 2007, Iran (78) | 0 | 50 grades I, II, and III |
| Takei et al., 2008, USA (9) | 10.4 | 46 grade I and 11 grade II (n = 57) No relation with grade, Ki67 or PR |
| Hirota et al., 2009, Japan (90) | 0 | 82 grades I, II, and III |
| Leães et al., 2010, Brazil (86) | 24.6 | 126 grades I, II, and III |
| Tao et al., 2012, China (10) | 60.5 | 162 grades I, II, and III. Weak expression for ER. No relation with recurrence. |
| Iplikcioglu et al., 2014, Turkey (14) | 0 | 26 grade I and 24 grades II and III |
ER, estrogen receptor; SD, standard deviation.